Skip to content
Calculator
Compare

KPV vs BPC-157

Last updated: November 4, 2026 · 6 min read · By the Grey Peptides Editorial Board

Close-up of a patient consulting a doctor with a clipboard in a medical setting
Photo by Thirdman on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Both were voted through by FDA's compounding advisory committee in July 2026, as reported 14, a recommendation FDA had not acted on as of October 27, 2026 15. KPV's nomination was for skin and wound uses, not gut disease 16.
  • KPV has never been tested in people. Its evidence is mouse colitis models and cell studies. BPC-157 has rodent gut studies and a few small human studies 9; its one study in a gut disease, in ulcerative colitis, is known only from a 2005 meeting abstract whose data FDA judged inadequate 12.
  • Neither peptide is an approved treatment for inflammatory bowel disease 17.

Side by side

KPV Low and BPC-157 Low are both graded low. The table is read from our encyclopedia entries.

FieldKPVBPC-157
Encyclopedia entryKPV Full entryBPC-157 Full entry
Molecule classPeptidePeptide
CategoryHealing & RecoveryHealing & Recovery
FDA statusResearch ChemicalResearch Chemical
Approved elsewhereNone recordedNone recorded
Evidence gradeLowLow
Half-lifeNot measuredShort systemic half-life (minutes) but prolonged tissue effect
FormulaC16H30N4O4C62H98N16O22
Molecular weight342.4 g/mol1,419.5 g/mol
WADA 2026Prohibited (S0 catch-all)Prohibited at all times (S0)
WADA 2027Prohibited (S0 catch-all)Prohibited at all times (S0)
In one lineA tripeptide from the tail of α-MSH: anti-inflammatory in mouse colitis and cell studies, never tested in people, and recommended for compounding by FDA's advisers in July 2026.A synthetic pentadecapeptide from gastric protein, widely studied in animal models for tendon, ligament, and gastrointestinal healing.
MechanismEnters gut epithelial and immune cells through the di/tripeptide transporter PepT1, which inflammation induces in the colon, and suppresses NF-κB and MAP kinase signalling; in airway cells it enters the nucleus and appears to block NF-κB p65's importin binding site. Its anti-inflammatory effect persisted in mice without functional MC1R, was not blocked by an MC3/4 antagonist and did not raise cAMP. All evidence is from cells and rodents.BPC-157 promotes angiogenesis via upregulation of VEGFR2 expression and activation of the Egr-1/NAB2 pathway, modulates nitric oxide signaling, and interacts with the dopaminergic and serotonergic systems in animal models. Effects are observed on tendon, ligament, muscle, bone, gastrointestinal tissue, and the blood-brain barrier. Despite extensive preclinical literature, no peer-reviewed human efficacy trials have been published as of 2026.
Sources in the entry1524
Study cards1421
Dosage pageDosage pageDosage page

What each is

KPV is lysine-proline-valine, the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone with anti-inflammatory effects. The tripeptide was first studied for reducing fever in rabbits, where it was less potent than alpha-MSH 1, and later for inflammation in the gut 2.

BPC-157 is a synthetic 15-amino-acid peptide that its developers call a stable gastric pentadecapeptide 3. Its early studies were of stomach ulcers in rats, in which intramuscular and oral doses reduced ulcer area 4, and its developers have since reported healing effects across many organs in animals 3.

KPV's evidence

In 2008, researchers showed that nanomolar amounts of KPV blocked NF-kappaB and MAP kinase signalling, two central inflammatory pathways, in human gut epithelial cells and T cells, that it entered cells through the transporter PepT1, and that KPV in drinking water reduced the severity of chemically induced colitis in mice 2. A second group found that KPV-treated mice recovered faster in two different colitis models 5. Later work loaded KPV into nanoparticles and hydrogels to target the inflamed colon in mice and rats 6. Every study is in cells or animals; no published study has given KPV to a person.

One study complicates the picture: mice engineered to make more of the PepT1 transporter in the gut developed more colitis-associated tumours, and KPV prevented tumours in normal mice but had different effects depending on PepT1 7. The implications for people are unknown.

BPC-157's evidence

BPC-157's gut evidence is also animal. Beyond the ulcer models, rats with obstructed bile ducts given BPC-157 had less jaundice, fluid build-up and liver damage 8. A 2026 systematic review that searched to June 1, 2026 found three small human studies, 30 people in all, and judged them of poor quality 9: a two-person intravenous safety pilot 10, an uncontrolled knee chart review 11 and a bladder-injection pilot; none involved the gut. FDA's May 2026 briefing counts five clinical studies, about 108 people, because it adds two older studies of BPC-157 given as an enema: one in healthy volunteers, and a randomised, double-blind, placebo-controlled study in ulcerative colitis that was reported only as a 2005 meeting abstract and whose data FDA judged inadequate to support efficacy or safety 12. So the one human trial in a gut disease exists only as that abstract, and no full report of it has been published that either count could include. A September 2026 report later described three dental patients given BPC-157 by injection with TB-500, ARA-290 and other drugs, without a control group 13.

What the July 2026 vote means

In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend both KPV and BPC-157 for the list of substances pharmacies may use in compounding, as reported (FDA has posted no tallies) 14 15. For KPV, FDA's reviewers had proposed not adding it, and the nomination was for wound healing and inflammatory skin conditions, not gut disease 16. That is advice, not approval. As of October 27, 2026, FDA had not acted, so neither can yet be lawfully compounded 15 17, and a listing would not be an FDA approval. Our July 2026 PCAC page sets out every vote.

On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of KPV and BPC-157 under the forms, routes and conditions in its Appendix B 18. The policy is non-binding, labelled a draft and open to revision; FDA has not added either to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).

What people with gut disease use instead

Neither peptide has been tested in people with ulcerative colitis or Crohn's disease 17, and neither is an approved treatment for them. Anyone considering KPV or BPC-157 should discuss it with their gastroenterologist before changing any treatment, and tell them about anything already taken.

Sport status

Both are prohibited at all times under the WADA Code: BPC-157 is named under S0, non-approved substances, and KPV falls under the same catch-all for substances with no approval for human use 17.

How the differences add up (as of October 27, 2026)

KPV has a coherent mechanism and positive mouse colitis studies but no human data at all. BPC-157 has a larger animal literature, a few small human studies 9, one of them a colitis trial known only from a meeting abstract that FDA judged inadequate 12, and so no usable human gut trial either. Both are investigational in every sense that matters for a patient. Our guide to reading a study explains why mouse results do not establish a human benefit.

Frequently asked questions

Is KPV or BPC-157 better for gut health?

Neither has been tested in people with gut disease. KPV has mouse colitis studies; BPC-157 has rat ulcer and liver studies.

Has KPV been tested in humans?

No. Every published KPV study is in cells or animals.

Are KPV and BPC-157 legal to compound?

Not yet. FDA's advisory committee recommended both in July 2026, but FDA had not acted as of October 27, 2026, so pharmacies could not lawfully compound them. On October 30, 2026, HHS, FDA's parent department, published a non-binding draft policy (91 FR 68526) saying it will not take enforcement action against 503A pharmacy compounding of either under set conditions; that is not a listing or an approval.

Sources

  1. Richards, D. B., et al. (1984). Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit. Peptides, 5(4), 815-7. PMID: 6333677
  2. Dalmasso, G., et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1), 166-78. PMID: 18061177
  3. Seiwerth, S., et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des, 24(18), 1972-1989. PMID: 29998800
  4. Xue, X. C., et al. (2004). Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol, 10(7), 1032-6. PMID: 15052688
  5. Kannengiesser, K., et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis, 14(3), 324-31. PMID: 18092346
  6. Xiao, B., et al. (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther, 25(7), 1628-1640. PMID: 28143741
  7. Viennois, E., et al. (2016). Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol, 2(3), 340-357. PMID: 27458604
  8. Sever, A. Z., et al. (2019). Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation. Eur J Pharmacol, 847, 130-142. PMID: 30690000
  9. Poolton, J. T., et al. (2026). Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg, 92(3). PMID: 42885452
  10. Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31(5), 20-24. PMID: 40131143
  11. Lee, E., et al. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 27(4), 8-13. PMID: 34324435
  12. U.S. Food and Drug Administration. FDA Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), briefing document for the July 23-24, 2026 Pharmacy Compounding Advisory Committee, dated May 11, 2026: five clinical studies found in PubMed and Embase (rectal enemas in 24 healthy subjects; a multicentre, randomised, double-blind, placebo-controlled enema study in ulcerative colitis, 53 randomised, reported only as a 2005 meeting abstract, its data judged inadequate to support efficacy or safety; intra-articular injections in 17 people with knee pain; an intravesical injection in 12 with interstitial cystitis; intravenous infusions in 2 healthy subjects), 108 people by its own counts. Read October 28, 2026. FDA
  13. Froum, S., et al. (2026). Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health, 7, 1907109. PMID: 42876687
  14. McDermott (law firm). Bulk-list bound? PCAC backs majority of peptides in two-day public meeting (July 27, 2026): tallies for all seven. Read October 27, 2026; FDA has posted no minutes or tallies. Other reports agree on every tally except epitalon's 'no' count (7-4-1 here and in the FDA Law Blog; 7-5-1 in RAPS Regulatory Focus). Cited without a link.
  15. U.S. Food and Drug Administration. July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting page (briefing documents for BPC-157 and KPV; no minutes or vote tallies posted). Re-read October 3 and October 27, 2026.
  16. U.S. Food and Drug Administration. July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee: briefing document for KPV (free base) and KPV acetate (nominated for wound healing and inflammatory skin conditions; FDA proposed not adding it); no minutes or vote tallies posted. Page last updated August 6, 2026; read October 27, 2026. FDA
  17. Grey Peptides dataset records for KPV and BPC-157 (status; WADA 2026 and 2027: BPC-157 named under S0, KPV S0 inferred; KPV vote against FDA staff's proposal; sources as recorded on each entry); read October 27, 2026.
  18. US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All comparisons

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead